CHASE LUTHER: Open Payments
NPI 1245600691 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 49 payments from 17 companies in 2025. Trend: 2023 $928 · 2024 $1,134 · 2025 $1,389
Food & beverage: $1,389
| Company | Payments | Amount |
|---|---|---|
| Smith+Nephew, Inc. | 2 | $244 |
| Boston Scientific Corporation | 3 | $201 |
| UROGEN PHARMA, INC. | 4 | $186 |
| Sumitomo Pharma America, Inc. | 22 | $161 |
| Merck Sharp & Dohme LLC | 1 | $108 |
| Astellas Pharma US Inc | 1 | $98 |
| Janssen Biotech, Inc. | 2 | $84 |
| IMMUNITYBIO, INC. | 1 | $59 |
| Endo USA, Inc. | 3 | $57 |
| Antares Pharma, Inc. | 3 | $48 |
Products named: STRAVIX PL, JELMYTO, ORGOVYX, AMS 700, XTANDI, KEYTRUDA, RYBREVANT, ANKTIVA.
Industry payments across NE — which companies pay providers there.
